Effect of prone and supine treatment positions for postoperative treatment of rectal cancer on target dose coverage and small bowel sparing using intensity-modulated radiation therapy

Yongqiang Yang¹,²,³#, Shang Cai¹,²,³#, Tianshu Zhao¹,²,³#, Qiliang Peng¹,²,³, Jianjun Qian¹,²,³, Ye Tian¹,²,³

¹Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China; ²Institute of Radiotherapy & Oncology, Soochow University, Suzhou 215004, China; ³Suzhou Key Laboratory for Radiation Oncology, Suzhou 215004, China

Contributions: (I) Conception and design: Y Tian, J Qian; (II) Administrative support: Y Tian, J Qian; (III) Provision of study materials or patients: Q Peng, T Zhao; (IV) Collection and assembly of data: S Cai, T Zhao; (V) Data analysis and interpretation: Y Yang, S Cai, T Zhao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Ye Tian; Jianjun Qian. Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou 215004, China. Email: dryetian@126.com; qianjianjun0628@126.com.

Background: To evaluate the influence of patient positioning on target dose coverage and dose distribution to the small bowel in intensity-modulated radiation therapy (IMRT) for rectal cancer patients.

Methods: Twenty-four consecutive rectal cancer patients undergoing postoperative radiation were selected and set up in either a prone or supine position. All patients received computed tomography (CT) scans before and during treatment (1–4 weeks). The CT images were defined as plan, 1W, 2W, 3W, or 4W. The plan, 1W, 2W, 3W and 4W CT images were fused. The clinical target volume (CTV) and planning target volume (PTV) delineated on the plan CT were copied onto the 1–4W CT. The treatment plans based on the plan CT were also copied onto the 1–4W CT. The target dose coverage rate was assessed. The couch-position data of the linear accelerator were acquired.

Results: Failure rates of the CTV and PTV target dose coverage were higher in the prone group than in the supine group (18.60% vs. 0% and 69.76% vs. 53.65%) during the treatment. The total couch-position deviation for the prone group (1.23±0.76 cm) was significantly greater than that of the supine group (0.28±0.18 cm; P=0.001). Compared with the supine group, the prone group had significantly less irradiated small bowel volume at V5 (P=0.003) and V10 (P=0.004).

Conclusions: The supine position maintained better target dose coverage and setup reproducibility in rectal cancer patients treated with IMRT. The prone position combined with the belly board can reduce the dose received by the small bowel.

Keywords: Rectal cancer; prone; supine; intensity-modulated radiation therapy (IMRT)

doi: 10.21037/tcr.2019.11.33

View this article at: http://dx.doi.org/10.21037/tcr.2019.11.33

Introduction

Patient positioning in rectal cancer radiotherapy should be determined based on setup reproducibility and the position that yields the lowest radiation dose to the organs at risk (OARs), especially the small bowel. Supine and prone positions are the most common treatment positions for rectal cancer patients undergoing radiotherapy. Previous studies have demonstrated that setup reproducibility for the different positions is an important influential factor of therapeutic outcomes (1-3). The supine setup is generally
Yang et al. Optimal patient positioning in IMRT for rectal cancer

Table 1 Patient demographic and clinical features (n=24)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Prone (n=12) (%)</th>
<th>Supine (n=12) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median [range]</td>
<td>55 [35–76]</td>
<td>53 [38–71]</td>
</tr>
<tr>
<td>Patients with stoma</td>
<td>6 (50.0)</td>
<td>5 (41.7)</td>
</tr>
<tr>
<td>Surgical procedure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mile’s</td>
<td>7 (58.3)</td>
<td>5 (41.7)</td>
</tr>
<tr>
<td>Dixon</td>
<td>5 (41.7)</td>
<td>7 (58.3)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7 (58.3)</td>
<td>6 (50.0)</td>
</tr>
<tr>
<td>Female</td>
<td>5 (41.7)</td>
<td>6 (50.0)</td>
</tr>
<tr>
<td>Pathologic T stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>3 (25.0)</td>
<td>2 (16.7)</td>
</tr>
<tr>
<td>T3</td>
<td>5 (41.7)</td>
<td>8 (66.7)</td>
</tr>
<tr>
<td>T4</td>
<td>3 (25.0)</td>
<td>2 (16.7)</td>
</tr>
<tr>
<td>Pathologic N stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>3 (25.0)</td>
<td>5 (41.7)</td>
</tr>
<tr>
<td>N1</td>
<td>5 (41.7)</td>
<td>4 (43.3)</td>
</tr>
<tr>
<td>N2</td>
<td>4 (33.3)</td>
<td>3 (25.0)</td>
</tr>
<tr>
<td>Distance from anal verge (cm), median [range]</td>
<td>7 [3–9]</td>
<td>6 [4–10]</td>
</tr>
</tbody>
</table>

associated with more stability during irradiation, easier setup, and more patient comfort, while the prone setup, especially on a belly board, is associated with a reduced dose to the small bowel. Due to the steep dose distribution gradient in intensity-modulated radiation therapy (IMRT), target dose coverage should be closely monitored. Although setup errors are accounted for in the margin expansion from clinical target volume (CTV) to planning target volume (PTV), the margin is also affected by factors such as radiotherapeutic technique, treatment position, and the immobilization device; thus, the margin must be confirmed by practical outcomes. This study compared the effect of the supine and prone positions on target dose coverage, thereby providing a reference for the optimal position in rectal cancer IMRT.

Methods

General clinical information

This study was conducted as a retrospective review. The recruitment period was from January to June 2018. Twenty-four patients with rectal cancer undergoing postoperative IMRT in our department were included and divided into the supine (n=12) and prone (n=12) groups. Table 1 summarizes the patients’ characteristics.

Immobilization and computer tomography (CT) scans

All patients were moved into the CT simulation (Siemens Emotion Duo) gantry head first. The supine group was immobilized using a carbon fiber base plate (CIVCO Medical Solutions, Orange City, Iowa, USA) and thermoplastic mask (Orfit, Wijnegem, Belgium). The prone group was immobilized using the belly board device (CIVCO Medical Solutions, Orange City, Iowa, USA). The CT simulation scans used a 5-mm slice thickness and spacing, ranging from the third lumbar vertebra to the lower anal verge. Before the CT scans, patients were instructed to fill their bladders and take the Gastrografin solution (500 mL) to better visualize the small bowel. CT simulation images were imported into the Pinnacle 9.0 treatment planning system (Philips Radiation Oncology, Fitchburg, Wisconsin, USA) and named “plan CT”. Next, the target volume was delineated, and the treatment was planned. After verification, the treatment plan was delivered to the patients on the Synergy accelerator (Elekta, Elekta Oncology Systems, Crawley, UK). CT scans were repeated under the same conditions on Fridays of the 1st–4th weeks of treatment and named 1W, 2W, 3W, and 4W, respectively.

Small bowel delineation

The small bowel delineation method was described by the Radiation Therapy Oncology Group (RTOG) and Banerjee et al. (4,5). Based on the contrast effect, the small bowel was delineated in every CT slice by contouring the outer surface with the upper border 1 cm above the PTV and the lower border at the end of the small bowel. The colon was excluded. All delineations were completed by one radiotherapy physician, with a window width of 600 and window level of 40.

Definitions of target volume and treatment planning

The target volume delineation and dose prescription were in accordance with the RTOG and international expert consensus guide (6,7). The CTV included the mesorectal...
area, presacral space, and internal iliac and obturator lymph node areas. The ischial-rectal fossa and the external iliac lymph node area were also included in some patients. The PTV was an expansion of the CTV: a 1 cm expansion in both the cranial and caudal directions and a 0.5 cm expansion to the left, right, front, and back. The prescribed dose was 50 Gy for 25 fractions. The Pinnacle 9.0 planning system was applied to set up the 7-field IMRT treatment plan based on the plan CT. The treatment plan used a 6 MV X-ray, cc convolution calculation, 0.3 cm computing grid, Elekta Synergy accelerator, and 40 MLC (multi-leaf collimator) pairs. The organs at risk (OAR) dose constraint was $V_{15} < 275 \text{ cc}$ for the small bowel, $V_{40} < 50\%$ for the bladder, and $V_{50} < 5\%$ for the bilateral femoral heads (5). The target dose coverage requirements were that 100% of the prescribed dose should include >95% of the PTV. The maximum PTV dose (Dmax) was <54 Gy. The 1–4W CT images were fused with the plan CT images. The two treatment plans based on the plan CT were copied to the 1–4W CT.

**Target dose coverage rates and failure rates of the two groups in different positions**

The CTV and PTV target dose coverage rates for 50 Gy were acquired from the dose-volume histograms (DVH) based on the plan CT and the 1–4W CT. The failure rate for the target dose coverage was defined as the ratio of the number of times that the target dose coverage was less than 95% to the total number of measurements.

**Evaluation of the small bowel dose volume**

The volume of the irradiated small bowel was defined as the absolute volume of V5–V50 (the volume of small bowel irradiated with 5–50 Gy in 5 Gy increments). Each patient’s small bowel volume (or the irradiated volume) was the mean volume of all CT slices. The small bowel volume (irradiated volume) of all patients over the entire therapy period was the median of each patient’s mean volumes.

**Prediction of the small bowel NTCP**

The built-in Lyman-Kutcher-Burman (LKB) calculation module in Pinnacle 9.0 was applied to predict chronic complications of the small bowel and was referred to as the chronic normal tissue complication probability (NTCP$_c$) (8-10). The parameters n (volume factor), m (slope of dose reaction curve), and TD50 (mean doses with a 50% probability of complications) were set as 0.15, 0.16, and 55 Gy, respectively (11). Complications were defined as a small bowel obstruction, perforation, or fistula. The logistic formula, NTCP = $(1+(V50/V)^k)^{-1}$, was used to calculate the acute toxicity of V15 (i.e., NTCP$_a$). V50 and k were set as 130 cc and 1.1, respectively (12). The method for obtaining NTCP statistical data for each or all patients was the same as that used to obtain the small bowel volume (or irradiated volume).

**Accelerator couch-position data**

Self-developed software was used in the Elekta MOSAIQ network (Elekta Oncology Systems, Crawley, UK) to acquire the couch-position data for each treatment cycle on the Synergy accelerator. Three directions (X, Y, and Z) were included: $+X$ and $-X$ represented the patient’s left and right, $+Y$ and $-Y$ represented the cranial-caudal direction (the beam and target ends of the accelerator), and $+Z$ and $-Z$ represented the ventral-dorsal (rising and falling directions of the accelerator couch). At the end of the radiotherapy, a total of 25 datasets were acquired for each patient in the 3 directions. The primary setup, which was completed by a team composed of a radiation oncologist, a radiation physicist and a technologist, was similar to the position at CT simulation due to the short time interval; thus, the couch position of the first therapy course was used as the baseline. The subsequent 24 couch-position datasets were compared with the baseline to generate the couch-position deviation for each therapy course and the mean deviation for the 25 fractions ($\Delta x$, $\Delta y$, $\Delta z$). The total couch-position deviation ($S$, cm) was calculated as:

$$S = \sqrt{\Delta x^2 + \Delta y^2 + \Delta z^2} \quad [1]$$

**Statistical methods**

SPSS 22.0 statistical software was used. A paired t-test was performed to compare the difference between the two groups. Pearson’s analysis was applied to analyze the correlation. P<0.05 was considered statistically significant.

**Results**

**Image data and treatment planning**

One hundred nine CT-scan image sets were obtained

© Translational Cancer Research. All rights reserved.  
Transl Cancer Res 2020;9(2):491-499 | http://dx.doi.org/10.21037/tcr.2019.11.33
from the 24 patients, among which 24 sets were plan, 2W, and 3W; 14 sets were 1W; and 23 sets were 4W. The 24 treatment plans based on the plan CT were copied to the 1-4W CT for a total 109 treatment plan sets. All treatment plans met the target dose coverage and OAR constraint requirements. Figure 1 shows the target volume and treatment planning of a supine patient and a prone patient.

**Couch-position deviation**

The mean couch-position deviations in the X, Y, and Z directions were 0.07±0.36, 0.02±0.92, and 0.08±0.36 cm, respectively. The total couch-position deviation in the prone group (1.23±0.76 cm) was significantly higher than that in the supine group (0.28±0.18 cm; P=0.001). The greatest deviations were seen in the Y (cranial-caudal) and Z (ventral-dorsal) directions (P=0.003 and P=0.003, respectively; Table 1).

**Target dose coverage**

Table 2 shows the patients’ target dose coverage rates. The two groups’ CTV target dose coverage rates (supine vs. prone) were 98.69±0.86% vs. 97.51±2.20% respectively.
while the PTV target dose coverage rates were 95.07±2.16% vs. 93.49±2.50% (P=0.120). Figures 2 and 3 demonstrate the CTV and PTV target dose coverage rates. The CTV dose coverage rates of the 12 supine patients were all above 95%. For five patients (41.67%) in the prone group, the CTV target dose coverage rate dropped below 95% eight times; the lowest was 84.09%. The prone group had higher CTV target coverage failure rates than the supine group (69.76% vs. 53.65%). Figure 1 shows the treatment planning and target volumes of 2 patients. Figures 1A,B,C,D,E shows that the supine patient's position was changed in the cranial-caudal direction. Figure 1G, H,I,J,K shows that the prone patient was moved in both the cranial-caudal direction and the left-right direction. Figure 4 shows the correlational analysis of the target dose coverage rate and total couch-position deviation, indicating a significant correlation (R=−0.683, P=0.000).

Small bowel dose volume and NTCP

Table 3 shows the small bowel dose volumes and NTCP for the 24 patients. Most of the dose volumes ranging from V5–V50 (excluding V50) were higher in the supine group than in the prone group, and the differences at V5 and V10 were statistically significant (P=0.003 and 0.004, respectively). The supine group showed greater acute and chronic small bowel toxicity (NTCP_A, NTCP_C) than the prone group: NTCP_A 58.95%±6.70% vs. 57.77%±8.65% (P=0.248); NTCP_C 4.78%±2.59% vs. 2.70%±1.67% (P=0.041).

Discussion

Sufficient target dose coverage should be prioritized when selecting patient positioning for rectal cancer IMRT. Setup reproducibility is usually affected by the patient’s physical condition, comfort, and immobilization devices. Poor setup reproducibility reduces target dose coverage. This study evaluated the target dose coverage in rectal cancer patients in the supine and prone positions. The doses received and the NTCP of the two patient groups were also evaluated. This study provides a reference for choosing optimal patient positioning.
positioning in rectal cancer IMRT.

Compared with the supine position, the prone position reduces the patient’s comfort and immobilization. In addition, the immobilizing thermoplastic mask cannot be used in combination with the belly board in most prone positions. The couch-position deviation was used in this study to describe the setup reproducibility. The setup reproducibility is affected by the interconnection of the center of the tumor, skin marks, immobilization device marks, and accelerator couch, for which the couch-position deviation is a very good indicator (13,14). Our results showed that the prone group had greater total couch-position deviation (S) than the supine group (P=0.001); the deviation was apparent in the cranial-caudal (P=0.003) and ventral-dorsal (P=0.003) directions. Similarly, previous literature has also reported that the prone position decreases setup reproducibility, especially in the cranial-caudal and ventral-dorsal directions, and the belly board increases setup error (15-18).

The prone position also reduced the CTV and PTV target dose coverage rates, although the differences were not statistically significant. Five patients (41.67%) in the prone group experienced 8 occurrences of the CTV target dose coverage rate dropping to <95%: twice at 1W, 4 times at 2W, twice at 3W, and none at 4W (2W was the greater). The lowest CTV target dose coverage rate was only 84.09% from the same patient who also had the lowest PTV target dose coverage rate of 77.10% (Figures 2,3). The CTV and PTV target dose coverage failure rates in the prone group were higher than those in the supine group. Further analysis revealed that the target dose coverage rate was correlated with the total couch-position deviation (R=−0.683, P=0.000; Figure 4), indicating that setup reproducibility can affect the target dose coverage rate, thereby providing references for patient setup with a fixed couch position. Because the geometric position between the PTV and CTV was fixed in this study, their relationship to the setup reproducibility was similar (Figure 4). However, the CTV target dose coverage rate was lower than that of the PTV, which could lead to insufficient dose distribution to target volume or even therapy failures. Therefore, the prone position has problems regarding stable target dose coverage.

Compared with the supine position, the prone position significantly reduced the small bowel dose volumes at V5 and V10 (P=0.003 and 0.004 respectively) but not at V15–50. Drzymala et al. selected 19 patients undergoing preoperative chemoradiation and performed simulation CT scanning in both the supine and prone (without the belly

<table>
<thead>
<tr>
<th>Dose-level</th>
<th>Total patients</th>
<th>Supine patients</th>
<th>Prone patients</th>
<th>t</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>V5 (cc)</td>
<td>250.27±115.92</td>
<td>362.48±117.71</td>
<td>208.70±63.35</td>
<td>3.70</td>
<td>0.003</td>
</tr>
<tr>
<td>V10 (cc)</td>
<td>236.72±95.05</td>
<td>289.10±98.75</td>
<td>203.55±61.95</td>
<td>3.64</td>
<td>0.004</td>
</tr>
<tr>
<td>V15 (cc)</td>
<td>178.58±47.13</td>
<td>180.68±46.72</td>
<td>172.83±47.74</td>
<td>1.29</td>
<td>0.223</td>
</tr>
<tr>
<td>V20 (cc)</td>
<td>159.02±54.19</td>
<td>196.58±57.65</td>
<td>144.42±49.60</td>
<td>1.30</td>
<td>0.218</td>
</tr>
<tr>
<td>V25 (cc)</td>
<td>109.45±43.25</td>
<td>109.45±46.10</td>
<td>112.56±42.10</td>
<td>−0.33</td>
<td>0.747</td>
</tr>
<tr>
<td>V30 (cc)</td>
<td>83.2±37.88</td>
<td>91.17±42.22</td>
<td>81.95±34.72</td>
<td>−0.37</td>
<td>0.716</td>
</tr>
<tr>
<td>V35 (cc)</td>
<td>68.12±31.18</td>
<td>72.67±33.98</td>
<td>62.44±29.62</td>
<td>−0.05</td>
<td>0.958</td>
</tr>
<tr>
<td>V40 (cc)</td>
<td>54.16±29.39</td>
<td>57.80±32.33</td>
<td>49.21±27.42</td>
<td>0.35</td>
<td>0.733</td>
</tr>
<tr>
<td>V45 (cc)</td>
<td>42.22±25.81</td>
<td>47.90±27.80</td>
<td>37.63±24.64</td>
<td>0.46</td>
<td>0.653</td>
</tr>
<tr>
<td>V50 (cc)</td>
<td>21.00±18.12</td>
<td>20.50±18.73</td>
<td>22.64±18.32</td>
<td>−0.02</td>
<td>0.979</td>
</tr>
<tr>
<td>Dmax (cGy)</td>
<td>5.34±3.28</td>
<td>5.34±3.28</td>
<td>5.34±3.29</td>
<td>0.01</td>
<td>0.989</td>
</tr>
<tr>
<td>NTCPc (%)</td>
<td>3.00±2.41</td>
<td>4.78±2.59</td>
<td>2.70±1.67</td>
<td>2.31</td>
<td>0.041</td>
</tr>
<tr>
<td>NTCPa (%)</td>
<td>58.64±7.72</td>
<td>58.95±6.70</td>
<td>57.77±8.65</td>
<td>1.22</td>
<td>0.248</td>
</tr>
</tbody>
</table>

Table 3 Small bowel dose volume and NTCP of 24 rectal cancer patients undergoing IMRT

$t$ and $P$ are the comparisons between the supine and prone groups. NTCPc and NTCPa are the chronic and acute normal tissue complication probabilities, respectively. IMRT, intensity-modulated radiation therapy; NTCPc, chronic normal tissue complication probability; NTCPa, acute normal tissue complication probability.
board) positions, along with three-dimensional conformal planning (19). Their results showed a significantly higher irradiated bowel volume (colon included) at V5 and V10 in the supine position, in the range of V5–45. These authors concluded that the dose received by the bowel did not differ between the two positions and that the supine position could be adopted for patients undergoing preoperative rectal cancer radiotherapy because the setup reproducibility was sound. The present study differed from theirs in that the patients were postoperative; the received dose measurement involved only the small bowel, not the colon; and the prone patients used belly boards. Further NTCP analysis in this study showed that the prone position reduced the chronic toxicity (NTCPc) but did not affect the acute toxicity (NTCPa). Previous reports also demonstrated that the prone position combined with the belly board in IMRT could markedly diminish the received dose to the small bowel, and the greatest reduction in irradiated volume occurred at low dose levels (1,2,20,21).

This study only observed the effect of patient positioning in setup errors and target dose coverage. The CTV was copied from the plan CT to the fused 1–4W CT without adaptive corrections; thus, the influence of physiological movements of the bladder and other organs was not considered. However, adaptive corrections to the target volume would have complicated the study and even obscured the effect of setup error in the target dose coverage.

Conclusions

The supine position could enable more stable target dose coverage in rectal cancer IMRT. The prone position combined with the belly board reduced the setup reproducibility, thereby affecting the target dose coverage. Although the prone position combined with the belly board could reduce the dose distribution to the small bowel, effective measures should be taken to ensure patient setup reproducibility.

Acknowledgments

We thank American Journal Experts for assisting in the preparation of this manuscript.

Funding: This work was supported, in part, by the Jiangsu Provincial Special Program of Clinical Medical Science (No. BE2018657), Jiangsu Medical Innovation Team (No. CXDT-37), and Medicine Outstanding Leader of Suzhou (No. 62), Scientific Research Program for Young Talents of China National Nuclear Corporation (to S Cai), Jiangsu Commission of Health medical research project (No. H2018115).
Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was approved by the ethics committee of The Second Affiliated Hospital of Soochow University (No. 2018067).

References


